Valganciclovir thrice weekly for prophylaxis against cytomegalovirus reactivation during alemtuzumab therapy

Leukemia

Volumn 23, Issue 4, 2009, Pages 800-801

  Hwang, Y Y ^a   Cheung, W W W ^a   Leung, A Y H ^a   Tse, E ^a   Au, W Y ^a   Kwong, Y L ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; INFECTION PREVENTION; NEUTROPENIA; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REACTIVATION;

EID: 64849107663     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.282     Document Type: Article

References (4)

1. Cheung WW, Tse E, Leung AY, Yuen KY, Kwong YL. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab. Am J Hematol 2007; 82; 108-111.
2. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J et al Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616-5623.
3. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008; 111: 1816-1819.
4. Han XY. Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer. J Clin Microbiol 2007; 45 1126-1132.